19 results on '"Yoon Yeup"'
Search Results
2. Effect of Ca2+ and Mg2+ concentration in culture medium on the activation of recombinant factor IX produced in Chinese hamster ovary cells
- Author
-
Kim, Won Hee, Kim, Jung-Seop, Yoon, Yeup, and Lee, Gyun Min
- Subjects
- *
MAGNESIUM ions , *CALCIUM ions , *BLOOD coagulation factor IX , *RECOMBINANT proteins , *CELL culture , *OVARIES , *HAMSTERS as laboratory animals , *BIOTECHNOLOGY - Abstract
Abstract: Factor IX (FIX) plays an important role in the blood coagulation cascade. When Chinese hamster ovary (CHO) cells producing recombinant human FIX were cultivated using a serum-free medium (SFM) containing 1.12mM of Ca2+ and 0.82mM of Mg2+, a significant amount of active FIX (aFIX) was converted into undesirable activated FIX (FIXa) in the later phase of batch culture. In an effort to improve aFIX production from CHO cells, the effect of Ca2+ and Mg2+ concentrations in the culture medium on the activation of aFIX to FIXa was investigated using SFM with various concentrations of Ca2+ and Mg2+ in the range of 0–1.0mM. The highest aFIX concentration of 1.36IU/mL was obtained at 1.0mM Ca2+ and 1.0mM Mg2+, but the activation of aFIX to FIXa in the later phase of culture was rapid and significant. In contrast, at 0.5mM Ca2+ and 1.0mM Mg2+, the aFIX concentration of 1.33IU/mL was obtained and did not decrease significantly in the later phase of culture. Taken together, lowering Ca2+ concentration from 1.0 to 0.5mM inhibits the activation of aFIX to FIXa in the later phase of culture, fortifying the robustness of downstream bioprocessing. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
3. Membrane-based hybridization capture of intracellular peptide nucleic acid
- Author
-
Shin, Duckhyang, Nam, Minwoo, Yoon, Yeup, and Kim, Meehyein
- Subjects
- *
NUCLEIC acid hybridization , *BIOLOGICAL membranes , *PEPTIDES , *SODIUM sulfate , *POLYACRYLAMIDE gel electrophoresis , *NUCLEIC acid probes , *WESTERN immunoblotting - Abstract
Abstract: Peptide nucleic acid (PNA) is a chimeric oligonucleotide with nucleotide-derived bases and a peptide backbone. Compared with natural nucleotides, PNA has several advantages, including improved stability and high sequence discrimination during duplex formation. Despite its potential for therapeutic application, analysis technologies have not been generalized, mainly due to ambiguous physiochemical properties resembling those of nucleic acids as well as protein. Here we present a PNA detection method: sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) followed by electrotransfer to a Western blotting membrane and then hybridization with a radiolabeled oligonucleotide probe. This method is useful for evaluating the quality of synthetic PNA and determining its intracellular localization. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
4. Double-filtered leukoreduction as a method for risk reduction of transfusion-associated graft-versus-host disease.
- Author
-
Chun, Sejong, Phan, Minh-Trang Thi, Hong, Saetbyul, Yang, Jehoon, Yoon, Yeup, Han, Sangbin, Kang, Jungwon, Yazer, Mark H., Kim, Jaehyun, and Cho, Duck
- Subjects
- *
GRAFT versus host disease , *INTERLEUKIN-7 , *BLOOD cells , *BLOOD products , *LEUCOCYTES , *DETECTION limit , *T cells - Abstract
Background: Transfusion-associated graft-versus-host disease (TA-GvHD) is caused by leukocytes, specifically T cells within a transfused blood product. Currently, the prevention of transfusion-associated graft-versus-host disease is performed by irradiation of blood products. With a sufficient reduction of leukocytes, the risk for TA-GvHD can be decreased. With consistent advances in current state-of-the-art blood filters, we herein propose that double filtration can sufficiently reduce leukocytes to reduce the risk for TA-GvHD. Materials: Thirty RBC concentrates were filtered with leukocyte filters, followed by storage at 1–6 oC for 72 hours, and then a second filtration was performed. Residual leukocytes in the double-filtered RBC units (n = 30) were assessed with flow cytometric methods, and an additional assay with isolated peripheral blood mononuclear cells (PBMCs) (n = 6) was done by both flow cytometric methods and an automated hematology analyzer. Quality of the RBCs after filtration was evaluated by hematological and biochemical tests. In vitro T cell expansion was performed using anti-CD3/CD28-coated Dynabeads or anti-CD3 (OKT3). In vivo experiment for GvHD was performed by using NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. Results: Double-filtered blood products showed residual leukocyte levels below detection limits, which calculated to be below 1200–2500 cells per blood unit. In vitro expansion rate of T cells showed that 6x103 and 1x103 cell-seeded specimens showed 60.8±10.6 fold and 10.2±9.7-fold expansion, respectively. Cell expansion was not sufficiently observed in wells planted with 1x102 or 10 cells. In vivo experiments showed that mice injected with 1x105 or more cells cause fatal GvHD. GvHD induced inflammation was observed in mice injected with 1x104 or more cells. No evidence of GvHD was found in mice injected with 103 cells. Conclusions: Our study suggests that additional removal of contaminating lymphocytes by a second leukodepletion step may further reduce the risk for TA-GvHD. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. Antitumor activity, pharmacokinetics, tumor-homing effect, and hepatotoxicity of a species cross-reactive c-Met antibody.
- Author
-
Park, Hyunkyu, Kim, Donggeon, Son, Eunju, Shin, Sunhwa, Sa, Jason K., Kim, Seok-Hyung, Yoon, Yeup, and Nam, Do-Hyun
- Subjects
- *
HEPATOTOXICOLOGY , *ANTINEOPLASTIC agents , *PHARMACOKINETICS , *PROTEIN-tyrosine kinases , *MET receptor , *CROSS reactions (Immunology) , *TUMOR growth - Abstract
The receptor tyrosine kinase c-Met plays critical roles in promoting tumor growth, invasion, metastasis, and angiogenesis in various types of cancer and is a promising therapeutic target. The development of a species cross-reactive therapeutic antibody could provide useful to comprehensive preclinical assessment in animal models. Towards this goal, we developed human/mouse cross-reactive c-Met antibodies using an antibody phage library. IRCR201, a c-Met antibody with species cross-reactivity, successfully inhibited the HGF/c-Met signaling pathway via degradation of c-Met and disruption of the binding with its partners, and demonstrated strong in vivo antitumor activity. In pharmacokinetic analysis, IRCR201 exhibited a nonlinear pharmacokinetic profile and showed rapid serum clearance at low dosage. Ex vivo fluorescence imaging and immunohistochemistry demonstrated strong tumor accumulation of IRCR201. Hepatotoxicity analysis revealed that IRCR201 does not significantly affect primary human and mouse hepatocytes. Serum chemistry analysis demonstrated that the alanine aminotransferase serum level was elevated in mice treated with 30 mg/kg IRCR201 than in PBS-treated mice, whereas the levels of aspartate aminotransferase and blood urea nitrogen did not significantly differ. Thus, IRCR201 is a potent therapeutic antibody that can disrupt the HGF/c-Met signaling axis and its species cross-reactivity would enable to evaluate precise biological activity in animal models. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
6. Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain.
- Author
-
Se Jeong Lee, Won Young Kang, Yeup Yoon, Ju Youn Jin, Hye Jin Song, Jung Hyun Her, Sang Mi Kang, Yu Kyeong Hwang, Kyeong Jin Kang, Kyeung Min Joo, Do-Hyun Nam, Lee, Se Jeong, Kang, Won Young, Yoon, Yeup, Jin, Ju Youn, Song, Hye Jin, Her, Jung Hyun, Kang, Sang Mi, Hwang, Yu Kyeong, and Kang, Kyeong Jin
- Subjects
- *
TREATMENT of brain cancer , *GLIOBLASTOMA multiforme treatment , *KILLER cells , *METASTASIS , *NATURAL immunity , *BLOOD cells , *CELL transplantation , *LABORATORY mice , *BRAIN tumor treatment , *GLIOMA treatment , *ANIMAL experimentation , *BRAIN tumors , *GLIOMAS , *LUNG tumors , *MICE - Abstract
Background: Glioblastoma multiforme (GBM) is characterized by extensive local invasion, which is in contrast with extremely rare systemic metastasis of GBM. Molecular mechanisms inhibiting systemic metastasis of GBM would be a novel therapeutic candidate for GBM in the brain.Methods: Patient-derived GBM cells were primarily cultured from surgical samples of GBM patients and were inoculated into the brains of immune deficient BALB/c-nude or NOD-SCID IL2Rgamma(null) (NSG) mice. Human NK cells were isolated from peripheral blood mononucleated cells and expanded in vitro.Results: Patient-derived GBM cells in the brains of NSG mice unexpectedly induced spontaneous lung metastasis although no metastasis was detected in BALB/c-nude mice. Based on the difference of the innate immunity between two mouse strains, NK cell activities of orthotopic GBM xenograft models based on BALB/c-nude mice were inhibited. NK cell inactivation induced spontaneous lung metastasis of GBM cells, which indicated that NK cells inhibit the systemic metastasis. In vitro cytotoxic activities of human NK cells against GBM cells indicated that cytotoxic activity of NK cells against GBM cells prevents systemic metastasis of GBM and that NK cells could be effective cell therapeutics against GBM. Accordingly, NK cells transplanted into orthotopic GBM xenograft models intravenously or intratumorally induced apoptosis of GBM cells in the brain and showed significant therapeutic effects.Conclusions: Our results suggest that innate NK immunity is responsible for rare systemic metastasis of GBM and that sufficient supplementation of NK cells could be a promising immunotherapeutic strategy for GBM in the brain. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
7. Spatiotemporal Evolution of the Primary Glioblastoma Genome.
- Author
-
Kim, Jinkuk, Lee, In-Hee, Cho, Hee Jin, Park, Chul-Kee, Jung, Yang-Soon, Kim, Yanghee, Nam, So Hee, Kim, Byung Sup, Johnson, Mark D., Kong, Doo-Sik, Seol, Ho Jun, Lee, Jung-Il, Joo, Kyeung Min, Yoon, Yeup, Park, Woong-Yang, Lee, Jeongwu, Park, Peter J., and Nam, Do-Hyun
- Subjects
- *
GLIOBLASTOMA multiforme , *GLIOBLASTOMA multiforme treatment , *CANCER relapse , *CANCER-related mortality , *TEMOZOLOMIDE , *MEDICAL care , *GENETICS - Abstract
Summary Tumor recurrence following treatment is the major cause of mortality for glioblastoma multiforme (GBM) patients. Thus, insights on the evolutionary process at recurrence are critical for improved patient care. Here, we describe our genomic analyses of the initial and recurrent tumor specimens from each of 38 GBM patients. A substantial divergence in the landscape of driver alterations was associated with distant appearance of a recurrent tumor from the initial tumor, suggesting that the genomic profile of the initial tumor can mislead targeted therapies for the distally recurred tumor. In addition, in contrast to IDH1 -mutated gliomas, IDH1 -wild-type primary GBMs rarely developed hypermutation following temozolomide (TMZ) treatment, indicating low risk for TMZ-induced hypermutation for these tumors under the standard regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
8. Translational Validation of Personalized Treatment Strategy Based on Genetic Characteristics of Glioblastoma.
- Author
-
Oh, Young Taek, Cho, Hee Jin, Kim, Jinkuk, Lee, Ji-Hyun, Rho, Kyoohyoung, Seo, Yun-Jee, Choi, Yeon-Sook, Jung, Hye Jin, Song, Hyeon Suk, Kong, Doo-Sik, Seol, Ho Jun, Lee, Jung-Il, Yoon, Yeup, Kim, Sunghoon, Nam, Do-Hyun, and Joo, Kyeung Min
- Subjects
- *
GLIOBLASTOMA multiforme treatment , *PHENOTYPES , *GLIOBLASTOMA multiforme , *MOLECULAR biology , *XENOGRAFTS , *ANIMAL models in research , *TARGETED drug delivery , *PATIENTS , *GENETICS - Abstract
Glioblastoma (GBM) heterogeneity in the genomic and phenotypic properties has potentiated personalized approach against specific therapeutic targets of each GBM patient. The Cancer Genome Atlas (TCGA) Research Network has been established the comprehensive genomic abnormalities of GBM, which sub-classified GBMs into 4 different molecular subtypes. The molecular subtypes could be utilized to develop personalized treatment strategy for each subtype. We applied a classifying method, NTP (Nearest Template Prediction) method to determine molecular subtype of each GBM patient and corresponding orthotopic xenograft animal model. The models were derived from GBM cells dissociated from patient's surgical sample. Specific drug candidates for each subtype were selected using an integrated pharmacological network database (PharmDB), which link drugs with subtype specific genes. Treatment effects of the drug candidates were determined by in vitro limiting dilution assay using patient-derived GBM cells primarily cultured from orthotopic xenograft tumors. The consistent identification of molecular subtype by the NTP method was validated using TCGA database. When subtypes were determined by the NTP method, orthotopic xenograft animal models faithfully maintained the molecular subtypes of parental tumors. Subtype specific drugs not only showed significant inhibition effects on the in vitro clonogenicity of patient-derived GBM cells but also synergistically reversed temozolomide resistance of MGMT-unmethylated patient-derived GBM cells. However, inhibitory effects on the clonogenicity were not totally subtype-specific. Personalized treatment approach based on genetic characteristics of each GBM could make better treatment outcomes of GBMs, although more sophisticated classifying techniques and subtype specific drugs need to be further elucidated. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
9. Immunoglobulin Fc domain fusion to apolipoprotein(a) kringle V significantly prolongs plasma half-life without affecting its anti-angiogenic activity.
- Author
-
Yu, Hyun-Kyung, Lee, Ho-Jeong, Ahn, Jin-Hyung, Lim, In-Hwan, Moon, Jae-Hoon, Yoon, Yeup, Yi, Lee S.H., Kim, Sun Jin, and Kim, Jang-Seong
- Subjects
- *
IMMUNOGLOBULINS , *APOLIPOPROTEINS , *TUMOR growth , *METASTASIS , *PHARMACOKINETICS , *ENDOTHELIAL cells , *NEOVASCULARIZATION inhibitors - Abstract
Angiogenesis is crucial for tumor growth and metastasis. Blocking this process is, therefore, a potentially powerful approach for the treatment of cancer. Human apolipoprotein(a) kringle V (rhLK8) is an angiogenesis inhibitor and is currently under development as an anti-cancer therapeutic. However, a relatively short in vivo half-life limits its widespread clinical use. This study was performed to evaluate whether fusion of an Fc domain to rhLK8 can extend plasma half-life. RhLK8-Fc fusion protein was expressed in CHO DG44 cells as a dimer and was readily purified by protein G affinity chromatography. The anti-angiogenic activity of rhLK8-Fc was similar to that of rhLK8, as determined by migration and tube formation assays with endothelial cells in vitro and a chorioallantoic membrane assay in vivo. Pharmacokinetic profiles in mice after single intravenous administration of rhLK8 or rhLK8-Fc showed that Fc fusion significantly increased the elimination half-life (t1/2) and the systemic exposure (AUCinf) of the protein, in parallel with a significant decrease in total clearance (CL). These data suggest that Fc fusion to rhLK8 is a powerful strategy for extending the plasma half-life of rhLK8 without affecting its anti-angiogenic activity, and could thus improve the clinical applicability of rhLK8. [ABSTRACT FROM PUBLISHER]
- Published
- 2013
10. Corrigendum to “Effect of Ca2+ and Mg2+ concentration in culture medium on the activation of recombinant factor IX produced in Chinese hamster ovary cells” [J. Biotechnol. 142 (2009) 275–278]
- Author
-
Kim, Won Hee, Kim, Jung-Seob, Yoon, Yeup, and Lee, Gyun Min
- Published
- 2009
- Full Text
- View/download PDF
11. Repeated intravenous infusion of human apolipoprotein(a) kringle V is associated with reversible dose-dependent acute tubulointerstitial nephritis without affecting glomerular filtration function
- Author
-
Lee, Ho-Jeong, Yu, Hyun-Kyung, Ahn, Jin-Hyung, Park, Yong-Keun, Yoon, Yeup, Kim, Jang-Seong, and Kim, Sun-Jin
- Subjects
- *
INTRAVENOUS therapy , *APOLIPOPROTEIN A , *NEPHRITIS , *GLOMERULAR filtration rate , *LABORATORY rats , *HISTOPATHOLOGY , *NEOVASCULARIZATION inhibitors , *BLOOD urea nitrogen - Abstract
Abstract: Because anti-angiogenic agents have shown various toxicities in clinical applications, the determination of their toxicities and their reversibility is important in the design of clinical trials. This study was performed to investigate the potential toxicities of an angiogenesis inhibitor, apolipoprotein(a) (Apo(a)) kringle V (rhLK8) in rats. Rats administered an intravenous (IV) bolus injection of rhLK8 (200mg/kg) for 7 days showed significant increases in serum blood urea nitrogen (BUN), creatinine and the BUN/creatinine ratio, which was compatible with acute tubulointerstitial nephritis (TIN) in pathological examination. Because anti-angiogenic therapies are usually based on long-term treatment strategies, rats were administered 200mg/kg/day of rhLK8 by intravenous infusion for 28 days. Rats receiving 200mg/kg of rhLK8 showed abnormal serological and histologic findings, but their levels returned to within normal ranges 2 weeks after the cessation of administration. The creatinine clearance rate (CCr) was not affected by rhLK8 treatment. Collectively, our data indicate that the intravenous infusion of rhLK8 at therapeutic doses may induce renal toxicities, such as acute TIN, but these toxicities are clinically tolerable and reversible with close monitoring and a recovery period. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
12. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection
- Author
-
Hong, Seol Hee, Byun, Young-Ho, Nguyen, Chung Truong, Kim, Soo Young, Seong, Baik Lin, Park, Songyong, Woo, Gyu-Jin, Yoon, Yeup, Koh, Jeong Tae, Fujihashi, Kohtaro, Rhee, Joon Haeng, and Lee, Shee Eun
- Subjects
- *
INTRANASAL medication , *FLAGELLIN , *INFLUENZA vaccines , *IMMUNE response , *IMMUNOGLOBULINS , *LABORATORY mice , *RESPIRATORY infections , *TOLL-like receptors , *IMMUNOASSAY , *OLFACTORY nerve , *EPITHELIUM , *PREVENTION - Abstract
Abstract: The influenza virus, a mucosal pathogen that infects the respiratory tract, is a major global health issue. There have been attempts to mucosally administer inactivated influenza vaccines to induce both mucosal and systemic immune responses. However, mucosally administered inactivated influenza vaccine has low immunogenicity, which is partially due to the lack of an effective mucosal adjuvant. The development of a safe and effective mucosal adjuvant is a prerequisite to the practical use of a mucosal inactivated influenza vaccine. We have previously demonstrated that a bacterial flagellin, Vibrio vulnificus FlaB, when mixed with antigen and administered intranasally, exerts a strong mucosal adjuvant activity by stimulating the Toll-like receptor 5 (TLR5). In this study, we tested whether the FlaB protein could serve as an effective mucosal adjuvant for an inactivated trivalent influenza vaccine (TIV) manufactured for humans; in a murine vaccination model, this vaccine consists of A/Brisbane/59/07 (H1N1 subtype), A/Uruguay/716/07 (H3N2 subtype), and B/Florida/4/06 (B type). Intranasal co-administration of the TIV with FlaB induced prominent humoral responses as demonstrated by high influenza-specific IgA levels in both the mucosal secretions and serum and significant specific IgG induction in the systemic compartment. The FlaB protein significantly potentiated influenza-specific cytokine production by draining lymph node cells and splenocytes. The FlaB mucosal adjuvant conferred excellent protection against a lethal challenge with a live virulent virus with high hemagglutination inhibition (HAI) antibody (Ab) titers. The FlaB did not accumulate in the olfactory nerve and epithelium, guaranteeing against a retrograde uptake into the central nervous system. These results suggest that FlaB can be used as a promising mucosal adjuvant for nasal inactivated influenza vaccine development. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
13. Antiangiogenic kringles derived from human plasminogen and apolipoprotein(a) inhibit fibrinolysis through a mechanism that requires a functional lysine-binding site.
- Author
-
Ahn, Jin-Hyung, Lee, Ho-Jeong, Lee, Eun-Kyoung, Yu, Hyun-Kyung, Lee, Tae-Ho, Yoon, Yeup, Kim, Sun-Jin, and Kim, Jang-Seong
- Subjects
- *
PLASMINOGEN , *APOLIPOPROTEINS , *FIBRINOLYSIS , *NEOVASCULARIZATION , *HOMOLOGY (Biology) , *LYSINE , *THROMBIN - Abstract
Many proteins in the fibrinolysis pathway contain antiangiogenic kringle domains. Owing to the high degree of homology between kringle domains, there has been a safety concern that antiangiogenic kringles could interact with common kringle proteins during fibrinolysis leading to adverse effects in vivo. To address this issue, we investigated the effects of several antiangiogenic kringle proteins including angiostatin, apolipoprotein(a) kringles IV9-IV10-V (LK68), apolipoprotein(a) kringle V (rhLK8) and a derivative of rhLK8 mutated to produce a functional lysine-binding site (Lys-rhLK8) on the entire fibrinolytic process in vitro and analyzed the role of lysine binding. Angiostatin, LK68 and Lys-rhLK8 increased clot lysis time in a dose-dependent manner, inhibited tissue-type plasminogen activator-mediated plasminogen activation on a thrombin-modified fibrinogen (TMF) surface, showed binding to TMF and significantly decreased the amount of plasminogen bound to TMF. The inhibition of fibrinolysis by these proteins appears to be dependent on their functional lysine-binding sites. However, rhLK8 had no effect on these processes owing to an inability to bind lysine. Collectively, these results indicate that antiangiogenic kringles without lysine binding sites might be safer with respect to physiological fibrinolysis than lysine-binding antiangiogenic kringles. However, the clinical signi-ficance of these findings will require further validation in vivo. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
14. Investigation of the biological indicator for vaccine efficacy against highly pathogenic avian influenza (HPAI) H5N1 virus challenge in mice and ferrets
- Author
-
Song, Min-Suk, Oh, Taek-Kyu, Pascua, Philippe Noriel Q., Moon, Ho-Jin, Lee, Jun Han, Baek, Yun Hee, Woo, Kyu-Jin, Yoon, Yeup, Sung, Moon-Hee, Poo, Haryoung, Kim, Chul-Joong, and Choi, Young Ki
- Subjects
- *
BIOINDICATORS , *VIRAL vaccines , *DRUG efficacy , *AVIAN influenza , *DRUG dosage , *INFLUENZA viruses , *HEMAGGLUTININ , *FERRETS as laboratory animals , *LABORATORY mice , *NEURAMINIDASE , *THERAPEUTICS - Abstract
Abstract: To investigate the biological indicator for vaccine efficacy against HPAI H5N1 virus challenge of varying clades, two inactivated whole-virus H5N1 vaccines containing the hemagglutinin (HA) and neuraminidase (NA) genes of either clade 2.2 A/EM/Korea/W149/06 (RgKoreaW149/06xPR8) or clade 2.5 A/Ck/Korea/ES/03 (RgKoreaES223N/03XPR8) virus in the background of A/PR/8/34 (H1N1) were generated by reverse genetics. Administration of the vaccines (2-dose 1.77, 3.5, 7.5 or 15μg of HA) elicited high HI titers in a dose-dependent manner. Mice immunized with RgKoreaW149/06xPR8 were completely protected from challenge against wild-type A/EM/Korea/W149/06 without clinical signs of infection. RgKoreaES223N/03XPR8 could not protect mice at 1.77μg while all immunized ferrets were completely protected. Two-dose (7.5μg) vaccinated mice (HI titer ≥320) and triple dose (7.5μg) vaccinated ferrets with RgKoreaES223N/03xPR8 (HI titer ≥640) protected vaccine recipients from mortality, inhibited nasal virus shedding and limited influenza virus tropism. Thus, these vaccines provided cross-protectivity in both models. More importantly, these results collectively suggested a positive correlation between vaccine-induced HI titers and inhibition of virus shedding including block of viral proliferation in major organs against a heterologous HPAI H5N1 virus. Although developing technologies or methods that will enable the reduction of administration dose/frequency remains to be resolved, our study demonstrated a considerable biological marker (≥640 HI titer) for full protection of the vaccinated hosts that could provide a preliminary basis for the assessment of complete immunization. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
15. Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes
- Author
-
Kim, Soo In, Shin, Duckhyang, Lee, Hyeon, Ahn, Byung-Yoon, Yoon, Yeup, and Kim, Meehyein
- Subjects
- *
TARGETED drug delivery , *SMALL interfering RNA , *HEPATITIS C treatment , *APOLIPOPROTEINS , *LIPOSOMES , *VIRAL proteins , *LIVER cells , *GENE silencing , *THERAPEUTICS - Abstract
Background/Aims: Hepatitis C virus (HCV) is one of the major human hepatic RNA viruses. Recently, we developed a liver-specific siRNA delivery technology using DTC-Apo composed of cationic liposomes (DTC) and apolipoprotein A-I (apo A-I). Here, we investigated whether DTC-Apo nanoparticles can systemically deliver siRNA into mouse hepatocytes expressing HCV proteins and inhibit their expression efficiently. Methods: A transient HCV model was constructed by hydrodynamic injection of plasmid DNA expressing viral structural proteins under hepatic control region and alpha1-antitrypsin promoter elements. Using this model, DTC-Apo containing HCV-core-specific siRNA was intravenously injected to assess antiviral activity as well as the duration of silencing. Results: Post-administration of DTC-Apo/HCV-specific siRNA at a dose of 2mg siRNA/kg inhibited viral gene expression by 65–75% in the liver on day 2. Improved activity (95% knockdown on day 2) without immunotoxicity was obtained by 2′-OMe-modification at two U sequences on its sense strand. Notably, the gene silencing effect of the modified siRNA was still maintained at day 6, while the unmodified one lost RNAi activity after day 4. Conclusions: Our results suggest that DTC-Apo liposome is a highly potential delivery vehicle to transfer therapeutic siRNA especially targeting HCV to the liver. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
16. Hepatic siRNA delivery using recombinant human apolipoprotein A-I in mice
- Author
-
Lee, Hyeon, Kim, Soo In, Shin, Duckhyang, Yoon, Yeup, Choi, Tae Hyun, Cheon, Gi-Jeong, and Kim, Meehyein
- Subjects
- *
APOLIPOPROTEINS , *SMALL interfering RNA , *DRUG administration , *LABORATORY mice , *RECOMBINANT proteins , *HIGH density lipoproteins , *CHOLESTEROL , *TARGETED drug delivery - Abstract
Abstract: Apolipoprotein A-I (apo A-I), the major protein component of high density lipoprotein (HDL), plays a key role in reverse cholesterol transport from peripheral tissues to liver or steroidogenic organs. Class B, type 1 scavenger receptor (SR-BI) is abundantly expressed in these target tissues and recognizes apo A-I of HDL for selective cholesteryl ester uptake. Recently, we reported the liver-targeting potential of plasma-derived apo A-I and the efficient delivery of therapeutic small interfering RNAs (siRNA) assembled with cationic liposome and apo A-I. In this study, we expressed and purified recombinant human apo A-I (rhapo A-I), low endotoxin grade, from an Escherichia coli expression system. The liver-targeting property of rhapo A-I was compared to that of plasma-derived apo A-I. Using a hepatitis C virus mouse model, intravenous administration of virus-specific siRNA with liposome and rhapo A-I significantly inhibited viral protein expression, demonstrating great promise for its use in clinical applications. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
17. Improved recombinant gene expression in CHO cells using matrix attachment regions
- Author
-
Kim, Jong-Mook, Kim, Jung-Seob, Park, Doo-Hong, Kang, Ho Sung, Yoon, Jaeseung, Baek, Kwanghee, and Yoon, Yeup
- Subjects
- *
HAMSTERS , *GENE expression , *MAMMALS , *TRANSGENE expression , *CHROMATIN - Abstract
The use of animal cells such as Chinese hamster ovary (CHO) cells for recombinant gene expression provides many advantageous features such as proper folding and post-translational modification of the recombinant protein. However, recombinant genes introduced into animal cells are often expressed at low levels mainly due to position effects from the neighboring chromatin context. The tedious and time-consuming selection and amplification procedure has been the major hurdle for using animal cell line such as CHO cells. To improve mammalian cell expression systems, we screened a variety of matrix/scaffold attachment region (MAR/SAR) elements for their ability to insulate transgene expression from the position effects in CHO cells. We found that the human β-globin MAR element is particularly effective as the frequency of β-Gal positive colonies was increased by up to 80%. The expression levels of these colonies were also enhanced about seven-fold. These improvements appear to be related to the increased copy numbers and a higher efficiency of expression of the integrated genes. When this element was used to express soluble TGF-β type II receptor (sTβRII) through the gene amplification system, the frequency of colonies expressing detectable amounts of sTβRII was much higher than that of the control vector. We could also generate high sTβRII producers with uniform growth properties by a simple two-step amplification process involving two concentrations of methotrexate. This eliminates the need to isolate individual colonies followed by multi-step treatments of methotrexate and thereby greatly simplifies this mammalian expression system. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
18. Human apolipoprotein(a) kringle V inhibits angiogenesis in vitro and in vivo by interfering with the activation of focal adhesion kinases
- Author
-
Kim, Jang-Seong, Yu, Hyun-Kyung, Ahn, Jin-Hyung, Lee, Ho-Jeong, Hong, Soon-Won, Jung, Kyung-Hwan, Chang, Soo-Ik, Hong, Yong-Kil, Joe, Young-Ae, Byun, Si-Myung, Lee, Suk-Keun, Chung, Soo-Il, and Yoon, Yeup
- Subjects
- *
APOLIPOPROTEINS , *CELL adhesion , *PLASMINOGEN , *NEOVASCULARIZATION - Abstract
Apolipoprotein(a) [apo(a)] contains the largest numbers of kringle domains identified to date. Of these, apo(a) kringle V shows significant sequence homology with plasminogen kringle 5, which is reported to be a potent angiogenesis inhibitor. To determine the effects of apo(a) kringle V on angiogenesis, it was expressed as a soluble protein (termed rhLK8) in Pichia pastoris and its in vitro and in vivo anti-angiogenic properties were examined. rhLK8 inhibited the migration of human umbilical vein endothelial cells in vitro in a dose-dependent manner. This function was associated with the down-regulation of the activation of focal adhesion kinase and the inhibition of the consequent formation of actin stress fibers/focal adhesions. rhLK8 also inhibited new capillary formation in vivo, as assessed by the chick chorioallantoic membrane assay and the Matrigel plug assay. These results indicate that rhLK8 may be an effective angiogenesis inhibitor both in vitro and in vivo. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
19. Semi-Automated Cell Panning for Efficient Isolation of FGFR3-Targeting Antibody.
- Author
-
Min, Byeongkwi, Yoo, Minyoung, Kim, Hyeree, Cho, Minjung, Nam, Do-Hyun, and Yoon, Yeup
- Subjects
- *
MEMBRANE proteins , *HIGH throughput screening (Drug development) , *CELL anatomy , *PROTEIN conformation , *IMMUNOGLOBULINS , *CANCER cells - Abstract
Phage display technology is a widely used practical tool for isolating binding molecules against the desired targets in phage libraries. In the case of targeting the membrane protein with its natural conformation, conventional bio-panning has limitations on the efficient screening of the functionally relevant antibodies. To enrich the single-chain variable fragment (scFv) pools for recognizing the natural conformation of the membrane targets, the conventional bio-panning and screening process was modified to include the semi-automated cell panning protocol. Using FGFR3-overexpressing patient-derived cancer cells, biotin-X-DHPE was introduced and coupled to Streptavidin-coated magnetic beads for use in the solution-phage bio-panning procedure. The resulting clones of scFv were compared to the diversity of the binding region, especially on CDR-H3. The clones enriched further by cell-based panning procedure possessed a similar binding site and the CDR-H3 loop structure. The resulting antibodies inhibited cell growth and induced target degradation. This process may be a useful tool for screening biologically related antibodies that recognize natural conformational structure on cell membrane protein. Furthermore, cell-based panning has the potential to further expand to a high-throughput screening (HTS) system and automation process. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.